Welcome to our dedicated page for Promis Neuroscie SEC filings (Ticker: PMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ProMIS Neurosciences Inc. (Nasdaq: PMN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K, proxy statements and other key documents. ProMIS is a clinical-stage biotechnology company focused on antibody and vaccine candidates targeting toxic misfolded protein oligomers in neurodegenerative and other misfolded protein diseases, and its filings offer detailed insight into corporate actions, governance and clinical program updates.
Through recent Form 8-K filings, ProMIS has reported material events such as the implementation of a one-for-twenty-five reverse stock split of its common shares, effective November 28, 2025, and subsequent notification from Nasdaq that the company regained compliance with the $1.00 minimum bid price requirement. Other 8-Ks describe the recommendation of an independent Data and Safety Monitoring Board to advance the PRECISE-AD Phase 1b trial of PMN310 to the final dose escalation cohort, the establishment of an at-the-market offering program, and the appointment and compensation of directors and executives.
The company’s definitive proxy statement on Schedule 14A outlines matters submitted to shareholders, including authorization of the share consolidation and procedures for a virtual special meeting. These materials provide information on share structure proposals, voting results and corporate governance practices. Additional filings reference press releases reporting quarterly financial results, which are incorporated by reference into Item 2.02 of Form 8-K.
On Stock Titan, ProMIS filings are updated in line with EDGAR and can be reviewed alongside AI-powered summaries that explain the significance of each document. Investors can quickly see how reverse stock split mechanics, Nasdaq listing compliance, at-the-market offerings, and clinical trial milestones are described in official filings. Over time, this page will also aggregate annual reports on Form 10-K, quarterly reports on Form 10-Q, and insider transaction reports on Form 4 as they are filed, helping users track both the scientific and capital markets dimensions of PMN’s development.
ProMIS Neurosciences Inc. large shareholder Ally Bridge–related entities report beneficial ownership of 6,070,405 common shares, representing 11.3% of the company’s common shares. The shares are held with shared voting and dispositive power across ABG Management Ltd., Ally Bridge Group (NY) LLC, Ally Bridge MedAlpha Master Fund L.P. and Fan Yu.
The filing also describes a January 29, 2026 Securities Purchase Agreement under which Ally Bridge purchasers agreed to buy 700,741 common shares at $12.13 per share and receive warrants for 700,741 additional shares with a $14.40 exercise price, exercisable immediately. The warrants expire on the earlier of 60 days after a PMN310 topline data Milestone Event or February 3, 2031, with the final closing of a broader approximately $75 million offering expected on February 3, 2026. The reporting persons state they acquired their holdings for investment and may consider additional transactions or strategic actions involving ProMIS.
ProMIS Neurosciences Inc. entered into a private financing with accredited investors to raise approximately $75 million in gross proceeds through a combination of common shares and warrants. The final closing is expected on February 3, 2026.
The company agreed to sell 6,815,296 common shares, 100,000 pre-funded warrants and common share purchase warrants for 6,915,296 shares. Common shares were priced at $10.77 and $12.13 per share for certain affiliates and insiders, with warrants exercisable at $14.40. If all warrants are exercised for cash, the company may receive up to an additional approximately $100 million.
ProMIS Neurosciences Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market. Nasdaq notified the company in writing that it now meets the $1.00 per share bid price rule and that the matter is closed.
The company had previously received a deficiency notice on January 8, 2025 after its common shares traded below $1.00 for 30 consecutive business days and was given up to two 180-day grace periods, extending to December 29, 2025. Its closing bid price was at least $1.00 for 10 consecutive business days from November 28, 2025 to December 11, 2025, which restored compliance with the bid price rule.
ProMIS Neurosciences Inc. (PMN) is implementing a reverse stock split of its common shares at a ratio of one-for-twenty-five. Effective as of 12:01 a.m. Eastern Time on November 28, 2025, every 25 issued and outstanding common shares will be automatically reclassified into one new common share, with no action required from shareholders.
The company is making proportional adjustments to equity incentive plan awards, stock options, other equity securities and all outstanding warrants, including both the number of shares issuable and the applicable exercise prices. The reverse split does not change the number of authorized common shares or their par value. No fractional shares will be issued; instead, shareholders entitled to a fractional share will receive cash in lieu of that fraction. Trading on The Nasdaq Capital Market will begin on a split-adjusted basis on November 28, 2025 under the existing symbol PMN, with a new CUSIP number 74346M505.
ProMIS Neurosciences Inc. reported the results of a special shareholder meeting held on November 17, 2025. Shareholders voted on a proposal to authorize a share consolidation of the company’s common shares at a ratio ranging from one-for-five up to one-for-twenty-five, with the exact ratio and timing within one year left to the Board of Directors’ discretion. Of the 53,811,110 common shares outstanding as of the record date, 24,328,153 shares, or about 45.21%, were present or represented by proxy.
The share consolidation proposal received 21,331,321 votes for, 2,939,187 votes against, and 57,645 abstentions, indicating strong support among participating shareholders. A second proposal, allowing adjournment of the meeting to solicit additional proxies if needed, also passed with 22,256,277 votes for, 1,786,586 votes against, and 285,290 abstentions, although the primary consolidation proposal was already approved.
ProMIS Neurosciences Inc. reported Q3 2025 results, highlighting larger R&D investment and recent financings. The company posted a net loss of $11.6 million for the quarter and $29.0 million year-to-date. Total operating expenses were $11.8 million in Q3, driven mainly by PMN310 development costs. Cash was $15.4 million at September 30, 2025, with net cash used in operations of $18.8 million for the nine months.
Management disclosed that these conditions raise substantial doubt about the company’s ability to continue as a going concern. To bolster liquidity, ProMIS raised gross proceeds of $21.6 million in July 2025 through discounted warrant exercises, new warrants in private placements, and a registered direct pre-funded warrant sale, plus $0.7 million net via an at-the-market offering. Common Shares outstanding were 53,811,110 as of September 30, 2025, and also reported as outstanding as of November 12, 2025.
ProMIS Neurosciences Inc. filed a Form 8-K to furnish its latest financial update. The company reported that a press release detailing its financial condition and results for the three and nine months ended September 30, 2025 has been made available. The release is posted on the company’s website under Investors/Financial Results and is included as Exhibit 99.1.
The filing lists the company’s common shares trading on The Nasdaq Capital Market under the symbol PMN. The press release is dated November 12, 2025 and is incorporated by reference under Item 2.02 (Results of Operations and Financial Condition).
ProMIS Neurosciences (PMN) reported an insider equity award on a Form 4. A director received an option to purchase 40,000 common shares at an exercise price of $0.45 per share on 10/22/2025, expiring on 10/22/2035. The option itself was granted for $0.
The filing states that 25% of the option vested on the grant date, with the remainder vesting in 36 equal monthly installments, subject to continued service. Following the transaction, 40,000 derivative securities were beneficially owned. The form was filed by more than one reporting person, and it notes that any proceeds from the sale of shares upon exercise will be remitted to Ally Bridge MedAlpha Master Fund L.P.
ProMIS Neurosciences (PMN) director filed a Form 3 reporting indirect holdings. The filing lists 6,058,738 common shares beneficially owned indirectly, held of record by Ally Bridge MedAlpha Master Fund L.P. The reporting person is a director and an employee of Ally Bridge Group (NY) LLC and disclaims beneficial ownership except to any pecuniary interest.
Derivative holdings include warrants for 7,348,604 common shares at $1.25 expiring 07/29/2030 and warrants for 1,066,674 common shares at $1.75 expiring 02/28/2029. The filing also lists additional warrants including tranches exercisable at $0.01; for those marked “(2)”, the warrants will expire when exercised in full.
The event date is 10/22/2025, and the ownership is reported as indirect (I) with the nature of ownership described in the footnote.
ProMIS Neurosciences (PMN) appointed Slanix Paul Alex, Pharm.D., to its Board of Directors effective October 22, 2025. The Board determined he is independent under Nasdaq listing standards, and committee compositions remain unchanged. Dr. Alex is President and Portfolio Manager for the Public Equity strategy at Ally Bridge Group, with prior investing and research roles at Tri Locum Partners, Consonance Capital, RBC, and Credit Suisse. He holds a Pharm.D. from St. John’s University and is a licensed pharmacist.
Under the company’s non-employee director compensation policy, Dr. Alex received an option to purchase 40,000 common shares, vesting 25% at grant with the balance vesting ratably over 36 months, and an annual cash fee of $40,000. Beginning with the 2026 annual meeting, he will be eligible for an additional option to purchase 20,000 shares each year, vesting on the earlier of the one-year anniversary or the next annual meeting. Per Ally Bridge Group’s governance policy, his equity awards and cash compensation are attributed to Ally Bridge MedAlpha Master Fund L.P.
FAQ
What is the current stock price of Promis Neuroscie (PMN)?
What is the market cap of Promis Neuroscie (PMN)?
